Imaging Diagnostic Systems Installs Additional CTLM(R) System for Schering AG, Studies
Fort Lauderdale. Imaging Diagnostic Systems, Inc. announced that Schering AG, Germany, has requested an additional CTLM(R) system as part of their collaborative efforts with IDSI to continue their studies of fluorescent compounds in their quest of breast cancer detection.
Schering AG and Imaging Diagnostic Systems previously signed a collaborative agreement designed to evaluate the advantages of new fluorescence dyes developed by Schering AG for the potential use of detecting breast cancer. Imaging Diagnostics' CTLM(R) system will be used in conjunction with Schering AG's dyes during Schering's clinical trials. The collaboration will assist in determining the potential benefits of using both technologies adjunctively to further enhance the CTLM(R) systems' capabilities in detecting breast cancer.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Diagnostics & Radiopharmaceuticals, Dermatology, as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products, Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life.
Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLM(R) system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography. The CTLM(R) system is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Last viewed contents
Infrareal takes over pharmaceutical and biotech site in Orth, Lower Austria from Takeda - "Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industrie"
Demystifying DNA hybridization kinetics
Going live to the beating heart
Turbo-charging pharmaceutical biotechnology simulations - New simulation technology is designed to make the production of biopharmaceuticals more efficient, cost-effective and comprehensible
How minimal genetic differences can turn healthy food into a deadly danger - You are what you eat - this old saying could take on a new dimension according to latest research results
PolyOne Suzhou Achieves ISO 13485 Certification for Healthcare Quality Management
